Incidence and Risk Factors for Extended-Spectrum beta-Lactamase-Producing Escherichia coli in Community-acquired Childhood Urinary Tract Infection.
- Author:
Jung Won LEE
1
;
Jee Sun SHIN
;
Jeong Wan SEO
;
Mi Ae LEE
;
Seung Joo LEE
Author Information
1. Department of Pediatrics, Ewha Womans University, College of Medicine, Seoul, Korea. sjoolee@ewha.ac.kr
- Publication Type:Original Article
- Keywords:
Extended-spectrum beta-lactamase;
Escherichia coli;
Community-aquired;
Urinary tract infection
- MeSH:
Anti-Bacterial Agents;
Ceftriaxone;
Child;
Community-Acquired Infections;
Cross Infection;
Disease Outbreaks;
Epidemiologic Studies;
Escherichia coli*;
Escherichia*;
Female;
Humans;
Incidence*;
Infant;
Penicillins;
Recurrence;
Retrospective Studies;
Risk Factors*;
Sterilization;
Treatment Outcome;
Urinary Tract Infections*;
Urinary Tract*
- From:Journal of the Korean Society of Pediatric Nephrology
2004;8(2):214-222
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Appropriate antibiotic therapy is important in childhood urinary tract infection and the selection of anibiotics is based on antimicrobial sensitivity of Escherichia coli. Extended- Spectrum beta-Lactamase(ESBL) is an enzyme produced by gram-negative bacilli that has the ability to hydrolyse penicillins, broad-spectrum cephalosporin and monobactam. There have been many reports of outbreaks of hospital infection by ESBL-producing organism. However, community-acquired infection with ESBL-producing organism are rare. This study was performed to retrospectively identify the incidence, characteristics and risk factors of ESBL(+) E. coli in community-acquired childhood UTI. METHODS: In 288 children admitted in Ewha Womans University Hospital with E. coli UTI from Mar 2001 to February 2003, ESBL was isolated. ESBL was confirmed by the utilization of an automatized machine(Vitek GNS 433 card) using liquid medium dilution method according to National Committee for Clinical Laboratory Standard. The clinical characteristics, risk factors, antimicrobial resistance and treatment effectiveness were compared with ESBL(-) E. coli UTI. RESULTS: Of 288 E. coli isolates, 31(10.8%) produced ESBL and 93.5%(29/31) occurred in infants younger than 6 month of age(P<0.01). No significant differences were noted in prior antibiotic use, prior admission history and underlying urogenital anomaly. Antimicrobial resistance was significantly higher in ESBL(+) E. coli compared with control patients (P< 0.05). Although ceftriaxone showed 100% resistance in ESBL(+) E. coli, bacteriologic sterilization rate after ceftriaxone therapy was higher(96.8%). However, the recurrence rate of febrile UTI within 6 months was higher(25.8%) than control patients(6.6%). CONCLUSION: Epidemiologic study is required to find out any new risk factors of community-acquired ESBL(+) E. coli UTI and changes in selection of empirical antibiotics shouldbe considered